Cas:148017-44-1 (2s,4s)-1-t-butoxycarbonyl-2-(N-T-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercapto-pyrrolidine manufacturer & supplier

Chemical Name:(2s,4s)-1-t-butoxycarbonyl-2-(N-T-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercapto-pyrrolidine

CAS.NO:148017-44-1

Synonyms:(2S,4S)-1-tert-butoxycarbonyl-2-(N-tert-butoxycarbonyl-N-sulfamoylaminomethyl)-4-mercaptopyrrolidine;(2S,4S)-tert-butyl 2-((tert-butoxycarbonyl(sulfaMoyl)aMino)Methyl)-4-Mercaptopyrrolidine-1-carboxylate;(2S,4S)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercaptopyrrolidine;(2S,4S)-2-[[(Aminosulfonyl)[(tert-butoxy)carbonyl]amino]methyl]-4-mercapto-1-pyrrolidinecarboxylic acid tert-butyl ester

Molecular Formula:C₁₅H₂₉N₃O₆S₂

Molecular Weight:411.53700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:166.42000

Exact Mass:411.15000

LogP:3.45380

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2S,4S)-1-tert-butoxycarbonyl-2-(N-tert-butoxycarbonyl-N-sulfamoylaminomethyl)-4-mercaptopyrrolidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S,4S)-2-[[(Aminosulfonyl)[(tert-butoxy)carbonyl]amino]methyl]-4-mercapto-1-pyrrolidinecarboxylic acid tert-butyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S,4S)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercaptopyrrolidine Use and application,(2S,4S)-tert-butyl 2-((tert-butoxycarbonyl(sulfaMoyl)aMino)Methyl)-4-Mercaptopyrrolidine-1-carboxylate technical grade,usp/ep/jp grade.

Related News: In picking McNamara for the over-the-counter unit, GSK is once again de facto standing behind Walmsley as the captain of the remaining pharma, which will stay focused on therapeutics and vaccines, despite pressure from Elliott Management to shuffle its top ranks. 5-Bromo-4,6-difluoropyrimidine manufacturers Another area AZ sees as a growth opportunity in China is rare diseases. In announcing its recent $39 billion acquisition of Alexion late last year, Soriot highlighted the potential to expand the Boston firm’s rare disease portfolio to China. n-(4,6-dimethylpyrimidin-2-yl)benzene-1,4-diamine suppliers Around 57% of Israel’s 9.3 million population has been vaccinated. Around 160 people are hospitalised with severe symptoms and daily new infections have spiked to more than 2,000, up from a handful of cases per day a few months ago. Verapamil hydrochloride vendor & factory.